UK's RQ Bio raises $115m for flu prevention drug

Investors pour $115M into RQ Bio in search of a preventive flu drug

The startup claims to have a “differentiated” antibody that can provide long-lasting protection against a variety of influenza strains.

UK's RQ Bio raises $115m for flu prevention drug

RQ Bio has raised $115m for clinical trials of RQB01, a one-shot antibody designed for strain-agnostic protection against seasonal influenza viruses.

RQ Bio Announces $115 Million (£85.5 Million) Series A Financing to Advance Long-Acting Antibody Programme RQB01 for Full Season Influenza Prevention

Mike Westby CEO of RQ Bio Financing led by Frazier Life Sciences with participation from new investors EQT Life Sciences, Forbion, Monograph, Wellington Management and...

RQ Bio raises $115m for long-acting flu antibody - European Biotechnology Magazine

London’s RQ Bio, a private biotech developing long-acting antibody therapeutics to prevent flu, has raised $115 million (£85.5 million/€101 million) in its Series A financing. The post RQ Bio raises $115m for long-acting flu antibody appeared first on European Biotechnology Magazine.